Mirum Pharmaceuticals’ Livmarli secures FDA nod to treat cholestatic pruritus
The approval of the IBAT inhibitor was based on findings from the Phase 3 MARCH study which included…
We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.
ContinueLearn More X
14 Mar 24
The approval of the IBAT inhibitor was based on findings from the Phase 3 MARCH study which included…
14 Mar 24
Under the agreement, Novartis made fixed payments to fully fund IFM Due’s research and development expenses for the…
13 Mar 24
The results of the late-stage trial showed a statistically significant and clinically meaningful changes in overall survival and…
12 Mar 24
The orphan drug exclusivity grants the drug seven years of US market exclusivity in its approved indication and…
12 Mar 24
The asset sale consists of the majority of the company's workforce and most of its clinical equipment and…
11 Mar 24
The approval was based on Wegovy's efficacy and safety results from the SELECT cardiovascular outcomes study in which…
11 Mar 24
The platform will consolidate administrative functions, facilitating better control and management for healthcare facilities.
08 Mar 24
The approval was based on the overall response rate (ORR) from the ROSEWOOD study in which ORR was…
07 Mar 24
The investment, announced by the UK government as part of Finance Minister Jeremy Hunt's spring budget, is expected…
06 Mar 24
Diasorin (FTSE MIB: DIA) announced today that it has received 510(k) clearance from the U.S. Food and Drug…